Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | PRCP | P42785 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749406 | 0.91 | PRCP (0.48) | LMNATSHRNPSR1PRCPALDH1A1 | |
| SCHEMBL14749424 | 0.91 | LMNA (0.47) | LMNATSHRNPSR1PRCPALDH1A1 | |
| SCHEMBL14749430 | 0.85 | PRCP (0.51) | LMNATSHRNPSR1PRCPSMN1; SMN2 | |
| SCHEMBL14749429 | 0.84 | LMNA (0.46) | LMNATSHRNPSR1PRCP | |
| SCHEMBL14749369 | 0.84 | PRCP (0.59) | PRCP | |
| SCHEMBL14749404 | 0.84 | PRCP (0.45) | LMNATSHRNPSR1PRCPMAPT | |
| SCHEMBL14749419 | 0.84 | PRCP (0.51) | LMNATSHRNPSR1PRCPMEN1 | |
| SCHEMBL14736597 | 0.83 | PRCP (0.48) | LMNATSHRNPSR1PRCPALDH1A1 | |
| SCHEMBL14749368 | 0.83 | PRCP (0.67) | PRCP | |
| SCHEMBL14749425 | 0.81 | PRCP (0.47) | LMNATSHRNPSR1PRCPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | LMNA 3736/4885TSHR 3548/4885NPSR1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.